This compound is a pharmaceutical intermediate specifically designed as a precursor for the synthesis of 18F-L-Dopa, a radiolabeled compound used in positron emission tomography (PET) imaging for Parkinson's disease research. It features a protected catechol structure with tert-butyl ester and carbamate groups, along with a boronic ester moiety, which facilitates radiofluorination.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2377146-66-0
Diethyl (2S)-2-[[4-(methylamino)benzoyl]amino]pentanedioate
pharmaceutical intermediate
Abiraterone N-Oxide
pharmaceutical intermediate
(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzene-1-sulfonate
pharmaceutical intermediate
4-hydroxyindole
pharmaceutical intermediate
tert-butyl (2S)-3-[4,5-bis(methoxymethoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoate
OMEJVTOXRPCWJF-QHCPKHFHSA-N
B1(OC(C(O1)(C)C)(C)C)C2=CC(=C(C=C2C[C@@H](C(=O)OC(C)(C)C)N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)OCOC)OCOC